Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.

Autor: Stella-Ascariz, Natalia, Montejano, Rocio, Rodriguez-Centeno, Javier, Alejos, Belen, Schwimmer, Christine, Bernardino, Jose I, Rodes, Berta, Allavena, Clotilde, Hoffmann, Christian, Gisslén, Magnus, de Miguel, Rosa, Esteban-Cantos, Andrés, Wallet, Cédrick, Raffi, François, Arribas, Jose R, NEAT 001/ ANRS 143 Study Group
Předmět:
Zdroj: Journal of Infectious Diseases; 11/15/2018, Vol. 218 Issue 10, p1523-1530, 8p
Abstrakt: Background: Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown.Methods: NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive HIV-infected adults. We compared changes in whole-blood telomere length measured with quantitative polymerase chain reaction in 201 randomly selected participants (104 raltegravir and 97 tenofovir disoproxil fumarate/emtricitabine). We performed multivariable estimative and predictive linear regression.Results: At week 96, participants receiving tenofovir disoproxil fumarate/emtricitabine had a statistically significant higher gain in telomere length than participants receiving raltegravir. Difference in mean telomere length change between groups (tenofovir disoproxil fumarate/emtricitabine minus raltegravir) from baseline to week 96 adjusted by baseline telomere length was 0.031 (P = .009). This difference was not significantly confounded by age, gender, known duration of HIV infection, CD4 (baseline/nadir), CD8 cells, CD4/CD8 ratio, HIV viral load (baseline/week 96), tobacco and alcohol consumption, statins, or hepatitis C.Conclusion: Antiretroviral-naive HIV-infected adults receiving ritonavir-boosted darunavir and tenofovir disoproxil fumarate/emtricitabine had a significant higher gain in blood telomere length than those receiving ritonavir-boosted darunavir and raltegravir, suggesting a better initial recovery from HIV-associated immunosenescence. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index